Table 5.
Deterministic and mean probabilistic ICERs for omalizumab versus SOC—base-case analysis
| Omalizumab | SOC | Incremental cost, £ | Incremental QALYs | ICER (£ per QALY) | Probability of omalizumab being cost-effective (at stated WTP threshold) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Cost, £ | QALYs | Cost, £ | QALYs | £20,000 | £30,000 | ||||
| Deterministic | 36,372 | 12.2 | 35,729 | 12.0 | 643 | 0.202 | 3183 | – | – |
| Probabilistic | 36,500 | 12.2 | 35,812 | 12.0 | 688 | 0.2 | 3566 | 95.4 % | 100 % |
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SOC standard of care, WTP willingness to pay